logo

Passion for Innovation. Compassion for Patients.™

Daiichi Sankyo Europe GmbH

European News

Daiichi Sankyo Partners With World Thrombosis Day

UK’s NICE recommends once-daily LIXIANA® (edoxaban) for preventing stroke and systemic embolism in patients with non-valvular atrial fibrillation

Target 70%: At ESC Congress 2015 Experts Discussed French, Italian and Austrian Initiatives for Better Blood Pressure Control

UK’s NICE recommends once-daily LIXIANA® (edoxaban) for the treatment and prevention of recurrent deep vein thrombosis and pulmonary embolism in adults

Real World ETNA Registries of New Once-Daily LIXIANA® (edoxaban) Start in Europe

Daiichi Sankyo and Plexxikon Announce Study Published in NEJM Demonstrates PLX3397 Induced Prolonged Tumor Regression in Tenosynovial Giant Cell Tumor (TGCT) in Most Patients

Daiichi Sankyo’s Once-Daily LIXIANA® (edoxaban) Approved in the EU for Stroke Prevention in Nonvalvular Atrial Fibrillation and for the Treatment and Prevention of Recurrent DVT and PE

Daiichi Sankyo Initiates Hokusai-VTE Cancer Study to Evaluate the Role of Edoxaban in Patients with Venous Thromboembolism Associated with Cancer

Expert report highlights urgent action needed to lessen the future impact of Atrial Fibrillation in Europe